Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLYMNASDAQ:GALTNASDAQ:ONTXNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$1.21-1.6%$1.25$1.05▼$9.21$83.12M-0.16188,624 shs189,457 shsGALTGalectin Therapeutics$2.42-26.4%$1.45$0.73▼$3.90$208.23M0.54405,619 shs4.32 million shsONTXOnconova Therapeutics$0.85$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsUNCYUnicycive Therapeutics$6.34-5.0%$0.75$2.02▼$11.00$84.38M2.01214,238 shs2.43 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio-1.63%-3.97%0.00%-6.92%+120,999,900.00%GALTGalectin Therapeutics-26.44%+76.64%+89.06%+52.20%+3.86%ONTXOnconova Therapeutics0.00%0.00%0.00%0.00%0.00%UNCYUnicycive Therapeutics+849.81%+830.44%+1,012.28%+832.35%+881.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLYMClimb Bio3.0956 of 5 stars3.60.00.00.02.52.51.3GALTGalectin Therapeutics1.8245 of 5 stars3.50.00.00.03.81.70.0ONTXOnconova TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUNCYUnicycive Therapeutics1.8944 of 5 stars1.85.00.00.03.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLYMClimb Bio 3.25Buy$9.00643.80% UpsideGALTGalectin Therapeutics 3.00Buy$6.00147.93% UpsideONTXOnconova Therapeutics 0.00N/AN/AN/AUNCYUnicycive Therapeutics 3.50Strong Buy$6.00-5.36% DownsideCurrent Analyst Ratings BreakdownLatest ONTX, GALT, UNCY, and CLYM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/6/2025CLYMClimb BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.005/27/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$9.005/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025CLYMClimb BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$7.004/21/2025UNCYUnicycive TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/11/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/1/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.50(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLYMClimb BioN/AN/AN/AN/A$3.15 per shareN/AGALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00UNCYUnicycive Therapeutics$680K1,178.59N/AN/A$0.07 per share90.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLYMClimb Bio-$73.90M-$2.38N/AN/AN/AN/A-43.95%-42.94%8/13/2025 (Estimated)GALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/11/2025 (Estimated)ONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%N/AUNCYUnicycive Therapeutics-$36.73M-$0.51N/AN/AN/AN/A-277.30%-61.53%N/ALatest ONTX, GALT, UNCY, and CLYM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/14/2025Q1 2025CLYMClimb Bio-$0.15-$0.31-$0.16-$0.31N/AN/A5/14/2025Q1 2025UNCYUnicycive Therapeutics-$0.14-$0.05+$0.09-$0.05N/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/A3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/A3/25/2025Q4 2024CLYMClimb Bio-$0.15-$0.13+$0.02-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLYMClimb BioN/AN/AN/AN/AN/AGALTGalectin TherapeuticsN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLYMClimb BioN/A14.2514.25GALTGalectin TherapeuticsN/A0.080.08ONTXOnconova TherapeuticsN/A2.792.79UNCYUnicycive TherapeuticsN/A1.641.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLYMClimb Bio69.76%GALTGalectin Therapeutics11.68%ONTXOnconova Therapeutics7.95%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipCLYMClimb Bio0.80%GALTGalectin Therapeutics50.10%ONTXOnconova Therapeutics3.30%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLYMClimb Bio967.58 million67.04 millionN/AGALTGalectin Therapeutics963.29 million31.58 millionOptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableUNCYUnicycive Therapeutics9126.41 million112.87 millionNot OptionableONTX, GALT, UNCY, and CLYM HeadlinesRecent News About These CompaniesUnicycive Therapeutics (NASDAQ:UNCY) Shares Gap Down - Time to Sell?June 20 at 11:55 AM | marketbeat.comUnicycive Therapeutics Inc trading halted, news pendingJune 19 at 12:42 AM | msn.comUnicycive to implement 1-for-10 reverse stock split to regain Nasdaq listingJune 18 at 7:40 PM | investing.comUnicycive Therapeutics, Inc. Announces Reverse Stock SplitJune 17, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 46.4% in MayJune 15, 2025 | marketbeat.comBrookline Capital Management Weighs in on UNCY Q3 EarningsJune 14, 2025 | americanbankingnews.comUNCY Q3 EPS Forecast Raised by Brookline Capital ManagementJune 12, 2025 | marketbeat.comKaplan Fox Announces an Investigation Into Unicycive Therapeutics, Inc. (UNCY) for Potential Securities Law ViolationsJune 11, 2025 | theglobeandmail.comRetail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28mJune 11, 2025 | finance.yahoo.comUnicycive Shares Slide as FDA Flags Issues Related to Kidney Drug ApplicationJune 10, 2025 | marketwatch.comUnicycive Therapeutics stock tumbles after FDA flags manufacturing issuesJune 10, 2025 | investing.comUnicycive Therapeutics Addresses FDA Deficiencies in OLC NDA Process, Awaiting Final Decision by June 2025June 10, 2025 | quiverquant.comUnicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on DialysisJune 10, 2025 | globenewswire.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Sees Significant Drop in Short InterestJune 3, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for UNCY Q2 Earnings?May 30, 2025 | marketbeat.comQ4 Earnings Estimate for UNCY Issued By HC WainwrightMay 29, 2025 | marketbeat.comUnicycive Therapeutics' (UNCY) "Buy" Rating Reiterated at HC WainwrightMay 28, 2025 | marketbeat.comUnicycive Therapeutics CEO Shalabh Gupta to Present at Upcoming Investor ConferencesMay 22, 2025 | quiverquant.comUnicycive Therapeutics to Present at Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comUnicycive Therapeutics Announces Time Change for 2025 Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comUnicycive Therapeutics, Inc.: Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONTX, GALT, UNCY, and CLYM Company DescriptionsClimb Bio NASDAQ:CLYM$1.21 -0.02 (-1.63%) As of 06/20/2025 04:00 PM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.Galectin Therapeutics NASDAQ:GALT$2.42 -0.87 (-26.44%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.41 -0.01 (-0.41%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Onconova Therapeutics NASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Unicycive Therapeutics NASDAQ:UNCY$6.34 -0.34 (-5.02%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.46 +0.12 (+1.89%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
